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ABSTRACT: With advancements in next-generation sequencing technology, a massive amount of sequencing data is generated,
which offers a great opportunity to comprehensively investigate the role of rare variants in the genetic etiology of complex
diseases. Nevertheless, the high-dimensional sequencing data poses a great challenge for statistical analysis. The association
analyses based on traditional statistical methods suffer substantial power loss because of the low frequency of genetic variants
and the extremely high dimensionality of the data. We developed a Weighted U Sequencing test, referred to as WU-SEQ,
for the high-dimensional association analysis of sequencing data. Based on a nonparametric U-statistic, WU-SEQ makes
no assumption of the underlying disease model and phenotype distribution, and can be applied to a variety of phenotypes.
Through simulation studies and an empirical study, we showed thatWU-SEQ outperformed a commonly used sequence kernel
association test (SKAT) method when the underlying assumptions were violated (e.g., the phenotype followed a heavy-tailed
distribution). Even when the assumptions were satisfied, WU-SEQ still attained comparable performance to SKAT. Finally,
we applied WU-SEQ to sequencing data from the Dallas Heart Study (DHS), and detected an association between ANGPTL
4 and very low density lipoprotein cholesterol.
Genet Epidemiol 38:699–708, 2014. © 2014 Wiley Periodicals, Inc.
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Introduction
Genome-wide association studies (GWAS) have been used
to uncover common genetic variants predisposing to com-
mon complex diseases. During the past decade, thousands
of new genetic variants have been identified from GWAS,
some with compelling biological plausibility for a role in dis-
ease etiology [Hindorff et al., 2009]. Despite such successes,
the genetic variants identified for most complex diseases
thus far can only explain a small fraction of the total her-
itability. Evolutionary theory suggests that rare variants are
likely to be recent and more deleterious mutations because
they are under less negative selective pressure [Boyko et al.,
2008; Fay et al., 2001; Kryukov et al., 2007; Pritchard, 2001;
Raychaudhuri, 2011]. Converging evidence from genetic
studies of complex diseases also suggests that complex dis-
eases are highly heterogeneous, and that familial subtypes
of complex diseases are frequently seen to be caused by rare
variants with large effects [Ahituv et al., 2007; Cohen et al.,
2004; Easton et al., 2007; Ji et al., 2008; Romeo et al., 2009].
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Nevertheless, current findings of rare variants predisposing
to complex diseases are still limited. With advancements in
high-throughput sequencing technology, researchers are now
able to comprehensively study the role of a massive amount
of sequencing variations, including both common and rare
variants, in human diseases. While the ongoing exome and
whole-genome sequencing studies hold great promise for
identifying new genetic variants, including rare variants, they
also pose great challenges for the statistical analysis ofmassive
amounts of sequencing data.
Single-locus analysis has been widely used in GWAS, such
analysis is, however, underpowered for detecting rare vari-
ants. Rare variants are anticipated to have larger effects than
common variants, but their low frequencies in the study pop-
ulation make them hard to detect. Moreover, the number of
single-locus tests required for sequencing studies is signif-
icantly larger than those required for GWAS studies, which
increases themultiple-testing burden. Therefore, as an essen-
tial alternative, a joint association analysis of genetic variants,
became popular in the association analysis of sequencing
data [Barnett et al., 2013; Chen et al., 2012; Ladouceur et al.,
2012; Lee et al., 2012; Li and Leal, 2008; Lin and Tang, 2011;
Madsen and Browning, 2009;Morgenthaler and Thilly, 2007;
Neale et al., 2011; Wei and Lu, 2011; Wu et al., 2011; Zhu
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et al., 2010]. A common strategy used in such analysis is to
first aggregate the effect of rare variants in a region (e.g., a
gene) via collapsing or weighting, and then to assess the joint
association of the variants with the phenotype of interest.
By aggregating information from multiple variants, the as-
sociation signal is enhanced and becomes more detectable.
Moreover, this greatly reduces the number of tests, which alle-
viates the multiple-testing issue. The commonly used meth-
ods for joint association analysis include the cohort allelic
sum test, the combined multivariate and collapsing method
[Li and Leal, 2008] and the weighted sum test [Madsen and
Browning, 2009]. Thesemethods, however, implicitly assume
the effects of different rare variants are in the same direc-
tion or magnitude. To address this limitation, the C-alpha
test [Neale et al., 2011] was proposed to consider the direc-
tion and magnitude of effects, whereby the expected vari-
ance and observed variance were compared in a case-control
setting. Another widely used semiparametric method for se-
quencing data analyses is the sequence kernel association
test (SKAT) [Wu et al., 2011], which is also robust for the
direction and magnitude of genetic effects. Moreover, built
based on the kernel machine regression, SKAT can adjust
for covariates, and is applicable to both binary and Gaussian
phenotypes.
Most existing methods for sequencing data analyses are
parametric based or semiparametric based, which rely on
certain assumptions. However, in practice, these assump-
tions may not be satisfied (e.g., the phenotype may not fol-
low a normal distribution in a sequencing study based on an
extreme phenotype design). When the assumptions are vio-
lated, the existing methods will likely have either decreased
power or inflated type I error. Nonparametric methods, such
as U-statistic-based methods, have shown their robustness
against underlying phenotypic distributions and/or under-
lying modes of inheritance [Li, 2012; Li et al., 2011; Schaid
et al., 2005; Wei et al., 2008, 2012, 2013]. VariousU-statistic-
based methods have been proposed to identify common
variants associated with binary or quantitative phenotypes.
Most of these methods use U-statistic to obtain multiple
group-wise scores, and then form test statistics to compare
scores amongdifferent groups. For case-control data analyses,
U-statistic is used to summarize the genetic information, and
then to compare scores between cases and controls [Schaid
et al., 2005]. For quantitative data analyses, U-statistic first
summarizes the phenotypic information, and then compares
scores among different genotype groups or multilocus geno-
type groups [Wei et al., 2008]. Because of different ways of
constructing U-statistics for binary and quantitative pheno-
types, it is challenging to provide a unifiedmethod under the
traditional U-statistic framework [Li, 2012].
The weighted U-statistic is a more general form of U-
statistic. It was developed in the 1980s–1990s [Gregory, 1977;
Serfling, 1981; Shieh, 1997] and has rarely been used in ge-
netic data analyses. By using a weighted U-statistic, genetic
information andphenotypic information canbe summarized
separately into the weight function and theU kernel, thereby
avoid the issue of group score comparison. Based on the
weighted U-statistic, we develop a Weighted U Sequencing
test (WU-SEQ), a unifiedmethod for sequencing data analy-
ses of various types of phenotypes (e.g., binary, ordinal, and
continuous). Moreover, we use a projection method in WU-
SEQ for covariates adjustment, and derive the asymptotic
distribution of the test statistic for an efficient assessment of
the significance of the association. The performance of WU-
SEQ was evaluated though extensive simulation studies, and
compared with a commonly used method, SKAT [Wu et al.,
2011]. Finally, we illustrate the proposed method by apply-
ingWU-SEQ to sequencing data from the Dallas Heart Study
(DHS).
Methods
AWeighted U for Association Analyses of Sequencing Data
Assume a population-based sequencing study with
N unrelated subjects and P single-nucleotide variants
(SNVs) located in a gene or a genetic region. Let yi and
Gi = (g i1, g i2, . . . , g iP ) denote, respectively, the phenotype
and the genotypes ofP variants of an individual i (1 ≤ i ≤ n),
where g ip (1 ≤ p ≤ P ) is coded as 0, 1, or 2. We use si,i′
and wi,i′ to denote the phenotypic similarity and the genetic
similarity between individuals i and i’, respectively. The
phenotypic similarity can be measured by any 2 degree
kernel function, si,i′ = h(yi, yi′), which satisfies the fi-
nite second moment condition (E F (h2(Y1,Y2)) < ∞).
While various kernel functions can be used to measure the
phenotypic similarities, in this paper,weuse the cross product
kernel, si,i′ = qiqi′ , where qi is the normal quantile of the rank
of yi , defined as qi = 
–1((rank(yi) – 0.5)/n), and 
–1(•)
is the inverse cumulative distribution function for standard
normal distribution. In the presence of ties, we assign them
an averaged rank. For example, if there are n0 numbers of
controls (i.e., yi = 0) and n1 numbers of cases (i.e., yi = 1),
an average rank is assigned to the group with the same
phenotype value (e.g., rank(yi ∈ {yi, yi = 0}) = (n0 + 1)/2
is assigned to the control group). Other than the quantile-
transformed cross product kernel, distance-transformed
phenotypic similarities, such as si,i′ = exp (–|yi – yi′ |) or
si,i′ = exp(–(yi – yi′)2) can be centralized and be used to
measure the phenotypic similarity. Nevertheless, as we
demonstrate below, the use of the quantile-transformed
cross product kernel leads to nice asymptotic properties.
Genetic similarity, wi,i′ , can be calculated using a vari-
ety of similarity functions. One of the commonly used
similarity functions for sequencing data is the weighted
Identity-by-State (IBS), which gives more weight to rare
variants,
wi,i′ =
P∑
p=1
2 – |Gi,p – Gi′,p |
ϒ
√
γp (1 – γp )
,
where γp is theminor allele frequency (MAF) for the p-th rare
variant, and ϒ =
∑P
p=1 2/
√
γp (1 – γp ) is used to standardize
the weight function so that wi,i′ ∈ [0, 1]. In addition to the
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weighted IBS, distance-transformed similarity functions can
also be used. For example, we could use wi,i′ = exp(–Di,i′),
whereDi,i′ is the distance function (e.g., Euclidian distance).
Given si,i′ and wi,i′ , the weighted U is formed to mea-
sure the association of P genetic variants with the disease
phenotype,
Uw =
1
n(n – 1)
∑
i =i′
wi,i′ si,i′, (1)
where si,i′ is the 2 degree U kernel and wi,i′ is the weight
function for the weighted U. When wi,i′ ≡ 1, we can cons-
truct anunweightedUbyusingonly thephenotype similarity,
Uuw =
1
n(n – 1)
∑
i =i′
si,i. (2)
In the weighted U, the summation is over all phenotypic
similarities weighted by the genotypic similarity, whereas
only the phenotypic similarity is used for the unweighted
U. Note that the U kernel, si,i′ , could be a positive/negative
value with a mean of 0. When there is no association
(i.e., under thenull), both theunweightedU and theweighted
U have an expectation of 0. When the genetic variants are
associated with the phenotype, we would expect genetic sim-
ilarities to be concordant with phenotypic similarities, where
larger weights are given to larger values of phenotypic simi-
larity. Therefore, the weightedU is expected to have a positive
value, while the unweighted U remains an expectation of 0
(i.e., the weighted U is expected to be greater than the un-
weightedU). Based on this concept, we could build an associ-
ation test by comparing the weightedU with the unweighted
U. The two U-statistics, however, are based on weights of
different scales (i.e.,wi,i′ vs. constant 1), therefore, a constant
c is introduced to balance the two weight functions. The test
statistic is then defined as
WUseq = Uw – cUuw , (3)
where the scaling constant c can be obtained by minimizing
the L2 norm distance between the two weight metrics, i.e.,
c = argmin
c>0
{∑i =i′ (wi,i′ – c)2}. Alternatively, we could choose
other types of c. For instance,we couldobtain cbyminimizing
the L1 norm distance between the two weight metrics, i.e.,
c = argmin
c>0
{∑i =i′ |wi,i′ – c|}.
Asymptotic Distribution of the Test Statistic
When the weighted U is significantly larger than the
rescaled unweightedU, we reject the null hypothesis and con-
clude there is an association between P genetic variants and
the phenotype. The P-value can be obtained by comparing
the observed test statistic,WUobsseq , with the null distribution,
i.e., Pr(WUseq > WUobsseq ). For a small sample size, a permuta-
tion test can be used for the P-value calculation. However, for
a large sample size and high-dimensional data, a permutation
test could be computationally intense. Therefore, we derive
the asymptotic distribution ofWUseq to efficiently assess the
significance level of the association.
We first rewrite the test statistic,WUseq, of equation (3) as
a weighted summation of si,i′ ,
WUseq =
1
n(n – 1)
∑
i =i′
ki,i′ si,i′ , (4)
where we define a new weight ki,i′ = wi,i′ – c . Denote Q =
(q1, q2, . . . , qN)T and K = {ki,i′ }n×n. If the phenotypic sim-
ilarity is measured by the cross product kernel, si,i′ = qiqi′ ,
WUseq is simplified to a quadratic form n(n – 1)WUseq
=
∑
i =i′ qiki,i′qi′ = Q
TKQ , with all the diagonal elements of
K equal to 0 (ki,i = 0). In such a case, it has a close connection
with the variance component score test in the linear mixed
model, except thatWUseq does not use information from the
diagonal terms (ki,i = 0), and does not assume a Gaussian
distribution of the phenotype.
The limiting distribution of U depends on ζ1 =
Var(E (h(Y1,Y2)|Y2)) [Serfling, 1981]. If ζ1 > 0, theU-statistic
is a nondegenerated U and asymptotically follows a nor-
mal distribution. If ζ1 = 0, the U-statistic is a degenerated
U and can be approximated by a mixture chi-squared dis-
tribution. By the definition of WUseq, we have E (q1q2|q2)
= q2E (q1) = 0, and therefore ζ1 = 0. Because ζ1 = 0, WUseq is
a degenerated weighted U-statistic. Its limiting distribution
can be approximated by a linear combination of chi-squared
random variables,
nWUseq ∼
∞∑
m=1
αm
n∑
l=1
λ˜l(χ
2
1,ml – 1), (5)
where χ21,ml are iid chi-squared random variables with one
degree of freedom. λ˜l and αm are generated from the eigen-
decomposition of the weight function ki,i′ and the kernel
function si,i′ [Serfling, 1981; Shieh et al., 1994; Wet and
Venter, 1973]. λ˜l (l = 1, . . . , n) are obtained from the eigenval-
ues λl of matrix K = {ki,i′ }n×n, with λ˜l = λl/(n – 1). {αm} are
the eigenvalues of a general kernel function, h(·,·), obtained
from the following decomposition,
h(q1, q2) =
∞∑
m=1
αmϕm(q1)ϕm(q2),
where {ϕm(•)} are the ortho-normal eigenfunctions
corresponding to αm. For the cross product ker-
nel, we can show that h(q1, q2) = q1q2 = 1ϕ1(q1)ϕ1(q2) +∑∞
m=2 0ϕm(q1)ϕm(q2), where ϕ1(q) = q (supplementary
Appendix S1).Thus,αm = 1{m=1},where 1 is an indicator func-
tion, and
∑∞
m=1 αm
∑n
l=1 λ˜l =
∑n
l=1 λ˜l = trace(K )/(n – 1) = 0.
The limiting distribution of WUseq can be simplified to
nWUseq
D→ χ2
,∞, where χ2
,∞ =
∑∞
l=1 λ˜lχ
2
1,l is a mixture
chi-squared distribution with mean 0 and finite variance
(Appendix A). Given the asymptotical distribution ofWUseq,
the P-value can then be calculated using the Davis method
[Davies, 1980].
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Adjusting Covariates With Confounding Effects
Assume we have J covariates, X i = (1, xi1, . . . , xiJ ), i
= 1, 2, ...,N. To adjust for the potential confounding effects,
we will first fit the transformed value of the phenotype, Q =
(q1, q2, ..., qN)T , with covariates X = (X 1,X 2, ...,XN)T , and
then use the residuals for the association test. Based on this
idea, we project Q onto the space spanned by X , and obtain
the prediction Qˆ , where Qˆ = X (XTX )–1XTQ . DenotingH =
I – X (XTX )–1XT and σˆ2 = (Q – Qˆ )T(Q – Qˆ )/(N – J – 1), we
can obtain the residuals, Qe = HQ/σˆ. It is easy to show that
Qe⊥X , therefore, a new response vector is attained that is
perpendicular to the space spanned by the covariates. The
test statisticWUseq can be reconstructed as
WUseq =
1
n(n – 1)
∑
i =i′
ki,i′q
e
i q
e
i′ .
Using the same argument as above,WUseq with covariates
adjustment can also be approximated by a linear combination
of chi-squared random variables,
nWUseq ∼
n∑
l=1
λ˜el χ
2
1,l.
λ˜el = λ
e
l /(n – 1) and {λel } are the eigenvalues of matrix K e ,
where K e = HKH . If the model is correctly specified and
the covariates (e.g., principle components) can capture the
confounding effects, the residual confounding is negligible.
However, in practical, we should consider potential issues,
such as nonlinearity of covariates and high correlations be-
tween genetic variables and covariates, before implementing
the covariate adjusting approach.Directly using the approach
without considering these issues may lead to inflated type I
error or power loss. For instance, principle components from
genetic data can be used to adjust for confounding effects due
to population stratification or population admixture. Never-
theless, if the genetic variants and/or the number of principle
components are insufficient, residual confounding could lead
to inflated type I error [Price et al., 2006].
Results
Simulation
We conducted simulation studies to evaluate the perfor-
mance of WU-SEQ, comparing it with one of the most com-
monly used methods, SKAT [Wu et al., 2011]. For all of the
simulations, we used genetic data from the 1000 genome
project [Abecasis et al., 2010] to mimic the real sequencing
data structure (e.g., LD pattern and allele frequency). Specifi-
cally, we used a 1Mb region from the genome (Chromosome
17: 7344328–8344327), and randomly chose a 30 kb segment
from that 1 Mb region for each simulation replicate (if not
specified otherwise). The average number of SNVs in the
sampled 30 kb segments is 194. The MAF of the SNV in
the genome region ranged from 4.50 × 10–4 to 4.99 × 10–1,
with a distribution highly skewed to rare variants (34.8% of
the variants with MAF < 0.001, 69.1% of the variants with
MAF < 0.01, and 80% of the variants with MAF < 0.03).
Similar to the SKAT simulation studies [Wu et al., 2011], we
selected a portion of the genetic variants with MAF < 0.03 as
functional SNVs. A number of individuals, ranging from 50
to 500, were randomly chosen as the study samples from all
of the available individuals in the 1000 genome project.
For each disease model, we simulated 1,000 data replicates
and obtained the type 1 error and power for both WU-SEQ
and SKAT. For SKAT, we used the link function according to
the distributions of phenotype (i.e., the logit link for a binary
phenotype and the identity link for a continuous phenotype)
[Wu et al., 2011]; for WU-SEQ, we used the L2 norm to
choose the constant c, and did not specify a phenotype dis-
tribution. To be consistent, both methods used a weighted
IBS to summarize genetic information. The type 1 error and
powerwereobtainedby calculating thepercentageofP-values
smaller than 0.05 from 1,000 data replicates.
Simulation I
We first simulated a series of disease models, without
considering covariates, and investigated the influence of
the direction and magnitude of effects on both methods.
Each data replicate was comprised 500 subjects. We consid-
ered four types of distributions for the phenotypes: binary,
Gaussian, Student’s t with two degrees of freedom, and
Cauchy. Binary and Gaussian phenotypes are typically ob-
served in population-based studies. The Cauchy-distributed
and t-distributed phenotypes represent continuous pheno-
types with more extreme values (i.e., heavy tailed). We used
the logistic model to simulate the binary phenotype,
logit(P (yi = 1)) = μ + Giβ,
where Gi and yi are the genotype and phenotype of the i-th
individual, respectively. β is a vector of regression parame-
ters, measuring the effects of the genetic variants. For each
simulation replicate, we sampled an effect vector from amul-
tivariate normal distribution, MVN(μβ1, σ2βI ), where 1 was
the vector of 1 and I was the identity matrix. For Gaussian
phenotypes, we simulated the model as
yi = μ + Giβ + εi,
where εi ∼ N(0, σ2). For the t-distributed phenotype, we
simulated the model as
yi = μ + Giβ + εi, εi ∼ tdf =2.
For the Cauchy type of phenotype, we used
yi ∼ Cauchy(ai, b).
ai and b were the location parameter and the scale parameter
of the Cauchy distribution, respectively, where ai = μ + Giβ
and b was a fixed value. For all four types of phenotypes,
we considered different directions of genetic effects. For the
first scenario, we assumed μβ = 0, whereby half of the func-
tional SNVs were deleterious and half of the functional SNVs
were protective. For the second scenario, we assumedμβ > 0,
whereby the majority of the functional SNVs were deleteri-
ous. For each scenario, we varied the percentage of functional
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Table 1. Type I error and power comparisons of WU-SEQ and SKAT under different direction and magnitude of effects
Binary Normal Student’s t Cauchy
Effecta Pctb SKAT WU-SEQ SKAT WU-SEQ SKAT WU-SEQ SKAT WU-SEQ
Type I error
Null 0 0.037 0.037 0.037 0.043 0.110 0.038 0.194 0.041
Power
A1 5 0.281 0.284 0.174 0.185 0.164 0.193 0.167 0.116
10 0.417 0.423 0.315 0.329 0.212 0.331 0.160 0.201
30 0.828 0.841 0.675 0.688 0.369 0.695 0.192 0.451
50 0.935 0.944 0.856 0.869 0.525 0.880 0.177 0.635
A2 5 0.065 0.073 0.085 0.093 0.140 0.134 0.190 0.095
10 0.166 0.173 0.155 0.163 0.192 0.288 0.175 0.179
30 0.539 0.547 0.524 0.527 0.471 0.784 0.199 0.578
50 0.773 0.780 0.790 0.798 0.733 0.960 0.187 0.818
a “Null” corresponds to the null model with no functional variant; “A1” corresponds to the setting where half of the functional rare variants have deleterious effect and the
other half of functional rare variants have protective effect; “A2” corresponds to the setting where all the functional rare variants have deleterious effects.
b Percentage of functional rare variants.
Table 2. Type I error and power comparisons of WU-SEQ and SKAT for different sample sizes
Binary Normal Student’s t Cauchy
Effecta Sample size SKAT WU-SEQ SKAT WU-SEQ SKAT WU-SEQ SKAT WU-SEQ
Type I error
Null 50 0.001 0.005 0.027 0.047 0.117 0.044 0.118 0.041
100 0.007 0.013 0.035 0.050 0.131 0.051 0.134 0.052
200 0.022 0.029 0.029 0.039 0.121 0.043 0.165 0.056
500 0.037 0.037 0.037 0.043 0.110 0.038 0.194 0.041
Power
A1 50 0.016 0.035 0.145 0.177 0.160 0.164 0.126 0.086
100 0.119 0.181 0.279 0.318 0.220 0.296 0.160 0.164
200 0.494 0.536 0.521 0.545 0.317 0.557 0.178 0.291
500 0.935 0.944 0.856 0.869 0.525 0.880 0.177 0.635
a “Null” corresponds to the null model with no functional variant; “A1” corresponds to the setting where half of the functional rare variants have deleterious effect and the
other half of functional rare variants have protective effect.
SNVs from 5% to 50%. The details of the simulation setting
were provided in supplementary Table S1.
We summarized the results in Table 1. From Table 1, we
found that WU-SEQ had well-controlled type 1 error rates
under various phenotype distributions. In contrast, SKAT
hadan inflated type1 error ratewhen theunderlyingdistribu-
tionwas the Cauchy distribution (0.194) or the t-distribution
(0.110). Similar to SKAT,WU-SEQ allows for different direc-
tionsof genetic effects (i.e., bothdeleterious andprotective ef-
fects). For both scenarios (i.e., μβ = 0 andμβ > 0), WU-SEQ
obtained comparable power or slightly higher power than
SKAT. As the percentage of the functional SNVs increased,
both WU-SEQ and SKAT gained improved power for binary
and Gaussian phenotypes. For the Cauchy-distributed and
t-distributed phenotypes, however, the power of WU-SEQ
was significantly higher than that of SKAT. With the Cauchy
phenotype, for example, SKAT’s power ranged from 0.167 to
0.192 for μβ = 0 and ranged from 0.175 to 0.199 for μβ > 0,
while the power of WU-SEQ increased from 0.116 to 0.635
for μβ = 0 and increased from 0.095 to 0.818 for μβ > 0.
Simulation II
In simulation II, we investigated the influence of sample
size on the performance of WU-SEQ and SKAT. We used the
same models as in simulation I to simulate binary, Gaussian,
Student’s t, and Cauchy phenotypes. For simplicity, we as-
sumedμβ = 0 and a fixed σ2β, and varied the sample size from
50 to 500 (supplementary Table S2). We assumed 0% of the
genetic variants were functional for the null model, and as-
sumed 50% of the genetic variants were functional for the
disease models.
The results were summarized in Table 2. Type 1 error rates
of WU-SEQ were well controlled at the 0.05 level for dif-
ferent sample sizes (i.e., 50, 100, 200, and 500) and various
phenotype distributions (i.e., binary, Gaussian, Student’s t,
and Cauchy), while the type 1 error of SKAT was inflated for
the Cauchy phenotype (0.118–0.194) and the t-distributed
phenotype (0.110–0.131). We also observed that both WU-
SEQ and SKAT had conservative type I error rates when
the study sample sizes were small. For instance, the type I
error rates of SKAT and WU-SEQ were 0.001 and 0.005, re-
spectively, when the sample size was 50 and the phenotype
was binary. The power of WU-SEQ increased as the sample
size increased for all four types of phenotypes. The power
of SKAT remained almost the same for the Cauchy phe-
notype (0.126–0.177) when the sample size increased. For
both the binary and Gaussian phenotypes, the power ofWU-
SEQ was comparable or slightly higher than that of SKAT,
while the power of WU-SEQ was significantly higher than
that of SKAT for the t-distributed and Cauchy-distributed
phenotypes.
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Table 3. Type I error and power comparisons of WU-SEQ and
SKAT when number of variants is much larger than sample sizea
Distribution
Effect Method Binary Normal Student’s t Cauchy
Type I error
Null SKAT 0.007 0.021 0.130 0.196
WU-SEQ 0.012 0.059 0.042 0.059
Power
A1 SKAT 0.153 0.896 0.708 0.264
WU-SEQ 0.304 0.933 0.864 0.558
a The average number of SNVs is 1,873 in these settings, while the sample size is set
as 100. The effect sizes are set as the same as in supplementary Table S2.
Additional simulations were also conducted to evaluate the
performance of WU-SEQ in the high-dimensional data set-
ting. Instead of using a 30kb segment, we randomly chose
a 500kb segment for each simulation replicate. The average
number of SNV for each subject was increased from 194 to
1,873. We fixed the sample sizes as 100 and simulated the
phenotype by using the settings presented in supplementary
Table S2. The result showed that WU-SEQ had well-
controlled type 1 error and good power performance when
the number of SNVswas larger than the sample size (Table 3).
Simulation III
In genetic association analyses, we often need to adjust im-
portant covariates (e.g., gender) for potential confounding
effects. Therefore, we conducted another set of simulations
to investigate the performance of WU-SEQ with the consid-
eration of covariates adjustment. In this simulation, we simu-
lated two covariates, x1,i ∼ Bernoulli(0.3) and x2,i ∼ N(0, 1)
for each subject. The binary phenotype was simulated by us-
ing
logit(P (yi = 1)) = μ + X iα + Giβ,
where X i = (x1,i, x2,i) and α = (α1, α2)T were the covariates
and the effects of the covariates, respectively. Similarly, we
used the linear model for the Gaussian phenotype,
yi = μ + X iα + Giβ + εi, εi ∼ N(0, σ2),
Table 5. Type I error and power comparisons ofWU-SEQ by using
different ca
Distribution
Effect Method Binary Normal Student’s t Cauchy
Type I error
Null WU-SEQL1b 0.013 0.048 0.056 0.041
WU-SEQL2c 0.013 0.049 0.058 0.043
Power
A1 WU-SEQL1 0.164 0.313 0.300 0.150
WU-SEQL2 0.170 0.322 0.306 0.159
a The sample size for this simulation is 100 and the effect sizes are set as the same as
in supplementary Table S2.
b In WU-SEQL1, we choose c by using L1 norm.
c In WU-SEQL2, we choose c by using L2 norm.
and the following model for the t-distributed phenotype,
yi = μ + X iα + Giβ + εi, εi ∼ tdf =2.
The Cauchy phenotype was simulated by using,
yi ∼ Cauchy(ai, b),where ai = μ + X iα + Giβ.
We varied the sample size from 50 to 500, and fixed the
percentage of functional rare variants at 50% for the disease
models (supplementary Table S3).
The results were summarized in Table 4. We found that
the projection method worked very well for WU-SEQ in
terms of covariate adjustment, and the type I error was well
controlled under different phenotype distributions. SKAT,
however, had a well-controlled type 1 error only when the
underlying assumptions were satisfied and the link function
was correctly specified. Similar to simulations I and II, we
observed comparable power between WU-SEQ and SKAT
for both the binary and Gaussian phenotypes, and WU-SEQ
had significantly higher power than SKAT for the Cauchy and
t-distributed phenotypes.We also found the type 1 error rates
were less conservative for studies with the binary phenotype
with covariate adjustment. This could be due to the fact that
the increased levels of residuals after covariate adjustment
lead to a better approximation of normal distribution.
In addition to the above simulations, we conducted sim-
ulations to investigate the performance of WU-SEQ under
different choices of c (Table 5) and different choices of
Table 4. Type I error and power comparisons of WU-SEQ and SKAT for covariate adjustment
Binary Normal Student’s t Cauchy
Effecta Sample size SKAT WU-SEQ SKAT WU-SEQ SKAT WU-SEQ SKAT WU-SEQ
Type I error
Null 50 0.027 0.027 0.040 0.059 0.084 0.069 0.128 0.063
100 0.030 0.034 0.042 0.054 0.106 0.064 0.131 0.065
200 0.028 0.028 0.036 0.050 0.110 0.060 0.173 0.061
500 0.036 0.036 0.043 0.048 0.115 0.065 0.194 0.047
Power
A1 50 0.060 0.071 0.128 0.165 0.297 0.400 0.140 0.112
100 0.156 0.210 0.306 0.342 0.483 0.664 0.164 0.159
200 0.522 0.545 0.500 0.527 0.682 0.882 0.163 0.262
500 0.929 0.934 0.850 0.855 0.884 0.997 0.180 0.554
a “Null” corresponds to the null model with no functional variant; “A1” corresponds to the setting where half of the functional rare variants have deleterious effect and the
other half of functional rare variants have protective effect.
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Table 6. Type I error and power comparison of WU-SEQ by using
normal quantile or ranka
Distribution
Effect Method Binary Normal Student’s t Cauchy
Type I error
Null WU-SEQRKb 0.017 0.02 0.031 0.032
WU-SEQQTc 0.017 0.047 0.057 0.050
Power
A1 WU-SEQRK 0.161 0.243 0.304 0.181
WU-SEQQT 0.161 0.314 0.322 0.169
a The sample size for this simulation is 100 and the effect sizes are set as the same as
in supplementary Table S2.
b In WU-SEQRK, we use cross product kernel based on rank of the phenotype value
without quantile transformation.
c In WU-SEQQT, we use cross product kernel with quantile transformation.
U kernel (Table 6). For different c based on L1 norm and
L2 norm, WU-SEQ had well-controlled type I error. How-
ever, WU-SEQ based on L2 norm had slightly higher power
than that based on L1 norm (Table 5). We also compared the
U kernel with the qunatile transformation and that without
the quantile transformation (by using ranks of phenotypes).
Both approaches could control the type I error. Neverthe-
less, using the quantile transformation let to higher power
for normal and t-distributed phenotypes (Table 6). In the
above simulation studies, we used 1,000 replicates to access
the type I error of WU-SEQ at the 0.05 level. An additional
simulation study was also conducted to access the type I error
at the 5 × 10–4 level by using 100,000 replicates. The result of
the simulation was summarized in supplementary Table S4.
From supplementary Table S4, we found that the type I error
was well controlled at the 5× 10–4 level. Moreover, the type I
error at 0.05 level estimated based on 100,000 replicates was
much closer to 0.05 than that based on 1,000 replicates.
Application to the Sequencing Data from the DHS
To further evaluate the performance of WU-SEQ and
SKAT, we applied both methods to the sequencing data from
the DHS [Romeo et al., 2009]. The DHS sequencing data
comprised four genes,ANGPTL3,ANGPTL4,ANGPTL5, and
ANGPTL6. We were interested in evaluating the association
of these genes with body mass index (BMI), cholesterol, and
very low density lipoprotein cholesterol (VLDL). Following
the previous study [Wu et al., 2011], we considered age,
gender, and race as covariates in the model. Prior to the as-
sociation analysis, we re-assessed the quality of the genotype
data. As a part of the quality assessment, we eliminated the
SNVs and subjects that had ahighmissing rate.After thequal-
ity control, 230 rare variants (54 SNVs, 63 SNVs, 61 SNVs,
and 52 SNVs are fromANGPTL3,ANGPTL4,ANGPTL5, and
ANGPTL6, respectively) and 2,598 subjects remained for the
analysis. In the analysis, random imputation based on allele
frequency was used to impute missing genotypes.
The distribution of the SNVs in the DHS was heavily
skewed to the rare variants (supplementary Fig. S2), wherein
93.5%, 87.4%, and 70% of all SNVs had an MAF of less than
3%, 1%, and 0.1%, respectively. Similar to previous studies
Table 7. The association of four candidate genes with three con-
tinuous phenotypes (i.e., BMI, cholesterol, and VLDL) in the Dallas
Heart Studya
BMI Cholesterol VLDL
Gene SKAT WU-SEQ SKAT WU-SEQ SKAT WU-SEQ
ANGPTL3 0.633 0.752 0.559 0.662 0.471 0.198
ANGPTL 4 0.121 0.255 0.16 0.316 0.105 0.007
ANGPTL 5 0.633 0.607 0.95 0.926 0.683 0.664
ANGPTL 6 0.874 0.773 0.025 0.059 0.433 0.453
All 4 genes 0.503 0.641 0.117 0.373 0.316 0.032
a P-value from the association analysis, adjusting for age, gender, and race.
[Wu et al., 2011], we selected SNVs with an MAF < 3% for
the analysis in order to detect associations due to rare vari-
ants. The distributions ofMAF for the four genes are given in
Figure 1. From Figure 1, we can see that the distributions of
MAF were highly skewed to the left, with the majority of the
SNVs having an MAF < 0.1%. The distributions of the three
phenotypes, BMI, cholesterol, and VLDL, can be viewed in
Figure 2. Among the three phenotypes, the distribution of
VLDL was heavily skewed to the left, which unlikely follows a
Gaussian distribution. We applied both WU-SEQ and SKAT
to the association analyses of 4 genes, with the considera-
tion of three covariates: gender, race and age (Table 7). To be
consistent, we used the weighted IBS for both WU-SEQ and
SKAT. WU-SEQ detected a strong association of ANGPTL4
(P-value = 0.007) with VLDL, while SKAT found only a
marginal association (P-value=0.105).To further explore this
finding, we combined all four genes into a gene set, and then
tested its association with VLDL (Table 7). The association
remained significant (P-value = 0.032) using WU-SEQ, but
not SKAT (P-value = 0.316).Noneof the four geneswas found
to be associated with BMI using either WU-SEQ or SKAT. A
marginal association was detected between ANGPTL6 and
cholesterol, with a P-value of 0.059 from WU-SEQ and a
P-value of 0.025 from SKAT. To evaluate the performance of
bothmethods for the binary phenotype,we dichotomized the
data into a highest quartile (coded as 1), and a lowest quartile
(coded as 0) for each phenotype (supplementary Table S5).
Overall,WU-SEQ attained similar results to SKAT. For exam-
ple, bothmethods found no association of all four genes with
BMI, amarginal association of all four genes with cholesterol,
and a significant association of all four genes with VLDL.
Discussion
Targeted, exome and whole-genome sequencing studies
are now underway for the discovery of new genetic variants,
particularly rare variants, associated with complex diseases.
With the emerging of a large amount of high-dimensional
sequencing data, great challenges have been posed to statis-
tical analyses of sequencing data. Conventional single-locus
analyses have been shown to have low power for analyz-
ing sequencing data, not only because of the low frequen-
cies of rare variants, but also because of the use of a more
stringent significance threshold. Joint association analyses of
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Figure 1. Distribution of SNVs with MAF < 0.03 for the four genes in the Dallas Heart Study.
Figure 2. Distributions of the three phenotypes in the Dallas Heart Study.
multiple genetic markers, as demonstrated in several studies,
can greatly reduce the dimensionality and improve perfor-
mance for sequencing data [Li and Leal, 2008; Madsen and
Browning, 2009; Neale et al., 2011; Tzeng et al., 2009; Wu
et al., 2011].
Nonparametric methods, such as U-statistic-based meth-
ods, have shown great promise for high-dimensional data
analysis, especially when the underlying phenotype distri-
butions and modes of inheritance are unknown. Several
U-statistic-based methods were recently adopted in genetic
association studies to detect common variants underlying
complex human diseases [Li, 2012; Li et al., 2011; Schaid
et al., 2005; Wei et al., 2012, 2013]. In this paper, we propose
a nonparametric method, WU-SEQ, for testing the joint as-
sociation of multiple SNVs with disease phenotypes. Built
under the framework of the weighted U-statistic, WU-SEQ
is robust against different underlying distributions of phe-
notypes. As demonstrated by the simulation study, WU-SEQ
had well-controlled type 1 error and attained high power
under binary, Gaussian, t-distributed, and Cauchy pheno-
types. In contrast, the performance of existingmethods, such
as SKAT, depends on satisfaction of the underlying assump-
tions. If the assumptions were violated (e.g., the distribution
followed a heavy-tailed distribution such as Cauchy), SKAT
had an inflated type 1 error, and had low power to detect
an association. Although SKAT can handle classic types of
phenotypes (e.g., the exponential family) by using appropri-
ate link functions, WU-SEQ can be applied to a wider range
of phenotypes without any distribution assumptions. In this
paper, we used the normal quantile to build the test statis-
tic. Alternatively, one can also use rank to construct the test
statistic. When the sample size is sufficiently large, we expect
that using quantile and using rankwould have similar results.
Nevertheless, for small sample sizes, using a normal quantile
couldbemorepowerful and less conservative thanusing rank.
Yet, when the distribution is heavily tailed (e.g., Cauchy), us-
ing rank could attain a slight advantage than using quantile
(e.g., having a well-controlled type I error rate) for small
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sample sizes (Table 6). As a similarity-based method, WU-
SEQ is flexible, to accommodate various types of data. The ge-
netic variants used to construct genetic similarity are not con-
strained to categorical data (e.g., SNV); they can also be count
data (e.g., CNV) and continuous data (e.g., expression data).
Forhigh-dimensional sequencingdata, thenumberof genetic
variants evaluated in the association analyses can be large.We
have showed in the simulation studies, when the number of
variants was much larger than sample sizes, WU-SEQ could
still control type I error and have good power performance
(Table 3). Similar as existingmethods (e.g., SKAT),WU-SEQ
is gene/region-based methods, and therefore can be directly
applied to whole-exome sequencing data. Nevertheless, chal-
lenges remain when applying the method to whole-genome
sequencing data because it requires a prior determination of
a region or a functional unit (e.g., gene). In addition, poten-
tial issues, such as determining genome-wide significance,
also need to be carefully considered for whole-genome se-
quencing data analysis. Although research has been initiated
to address these issues [Xu et al., 2014], further investigation
is much needed on these topics.
In WU-SEQ, we first summarize the information from
multiple markers into genetic similarities, and then evaluate
the genetic similarities with the corresponding phenotypic
similarities. If the genetic similarities are concordant with the
trait similarities,we anticipate a large value of the test statistic,
fromwhichwe could infer an association. In this paper,weuse
a weighted IBS to construct genetic similarity, which assigns
more weights to rare variants. Other types of genetic similar-
ity metrics can also be used, such as those consider interac-
tions. Prior knowledge can also be incorporated, by assigning
different weight for each variant according to their biological
plausibility. To measure the phenotype similarity, we use the
cross product kernel, si,i′ = h(qi, qi′) = qiqi′ , which lead to
nice asymptotic properties of the test statistic. Nevertheless,
we can use other types of kernel functions for the phenotype
similarity. If the kernel function satisfies two regularity con-
ditions, E F (h2(Y1,Y2)) < ∞ and Var(E (h(Y1,Y2)|Y2)) = 0,
we can calculate the asymptotic P-value by approximating
the weighted U to a linear combination of chi-squared vari-
ables. Even if the two conditions are not satisfied, we can still
use permutation to obtain the P-value of the association test.
The choice of the genetic- or phenotype-similarity metrics
depends on the underlying disease model, which could lead
to different performance. For example, when the percent-
age of risk variants increases and/or when the effect sizes of
risk variants follow one direction, the burden tests are ex-
pected to be more powerful than WU-SEQ. In this case, we
can use genetic similarities accommodating the underlying
disease models. One of the strategies is to first collapse all ge-
netic variants by weighted sum and then calculate the genetic
similarity.
Although joint association analyses greatly reduce the di-
mensionality for sequencing data, the computation could
be intense if a permutation test is used. We derived the
asymptotic distribution for WU-SEQ to facilitate the high-
dimensional data analysis. When the sample size of a study is
small, asymptotic propertiesmay not hold and a permutation
test can be used.We also use a projectionmethod inWU-SEQ
to take covariates into account. Through simulations and a
real data analysis, we found the covariate-adjusted WU-SEQ
was robust to different types of phenotype distributions. In
addition, we found thatWU-SEQhad almost the same power
as SKATwhen the phenotype followed Gaussian distribution
and covariates were not considered. The reason is that SKAT
uses a variance component score test, and WU-SEQ has a
close connection with the variance component score test for
the Gaussian-distributed phenotype. In fact, when covariates
are not considered, SKAT can be viewed as a special case of
WU-SEQ by using the cross product kernel without quantile
transformation. When covariates are considered, especially
when the phenotype does not follow the Gaussian distribu-
tion (i.e., the link function in SKAT is not an identity link),
WU-SEQ could attain more computational efficiency than
SKAT. In SKAT, one needs to first fit the null model using
a generalized linear model, which involves iterative estima-
tion. Furthermore, the calculation of a projection matrix in
SKAT involves additional matrix multiplications (i.e., cal-
culating H = V – VX (XTVX )–1XTV in SKAT vs. calculating
H = I – X (XTX )–1XT inWU-SEQ, whereV is the covariance
matrix estimated from the nullmodel), and the calculation of
the limiting distribution in SKAT involves an additional large
matrix decomposition (i.e., calculating H1/2KH1/2, where
H1/2 need to be calculated from an eigen-decomposition of
the H matrix). The covariate-adjusted WU-SEQ does not
require iterative estimation and needs less matrix multipli-
cation and decomposition, which offers a greater computa-
tional advantage over SKAT.
In the analysis of theDHSstudy,WU-SEQdetected a strong
association ofANGPTL 4withVLDL. By further studying the
distribution of VLDL, we found the distribution was heav-
ily skewed, which does not fit the normal assumption. The
advantages of WU-SEQ are not limited to this specific case;
the method could be useful for other cases (e.g., small sam-
ple sequencing studies and sequencing studies with extreme-
phenotype design). A recent version of SKAT also considers
the extreme phenotype by assuming a truncated Gaussian
distribution [Barnett et al., 2013].While SKATneeds tomake
adjustments and certain assumptions for the truncateddistri-
bution of extreme phenotypesWU-SEQ, as a nonparametric
method, can be directly applied to studieswith extreme-value
phenotypes.
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Appendix A
We first introduce a regularity condition on the weight
function ki,i′. Because 0 ≤ wi,i′ ≤ 1 and ki,i′ = wi,i′ – c , we
have 0 ≤|ki,i′ |≤ c ′, where c ′ is a positive constant. Based on
this, we have lim
n→∞
1
n(n–1)
∑
i =i′
k2i,i′ = C, whereC is also a positive
constant. Then, we can show,
E (χ2
,∞) =
∞∑
l=1
λ˜lE (χ
2
1,l) =
∞∑
l=1
λ˜l = 0,
and
Var(χ2
,∞) =
∞∑
l=1
λ˜2l Var(χ
2
1,l)
= lim
n→∞
2
(n – 1)2
n∑
l=1
λ2l
= lim
n→∞
2
(n – 1)2
trace(KK )
= lim
n→∞
2
(n – 1)2
∑
i =i′
k2i,i′
= 2C.
Based on this result, we can conclude that χ2
,∞ has zero
mean and finite variance, which implies that
√
nWUseq is
degenerated, i.e.,
√
nWUseq
p→ 0.
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